Results 101 to 110 of about 1,454 (181)

Effects of anti-calcitonin gene-related peptide medications on blood pressure in people with migraine: Review of FDA submission packages

Cephalalgia Reports
Background Several monoclonal antibodies (mAbs) and small molecule antagonists (gepants) targeting calcitonin gene-related peptide (CGRP) effectively prevent migraine.
Pratheeshan Sabeshan, Anthony Rodgers, Faraidoon Haghdoost   +2 more
doaj   +1 more source

Patient Preferences for Episodic Migraine Medications: A Discrete Choice Experiment of Self-Injectable Versus Oral Treatments Targeting Calcitonin Gene-Related Peptide Pathway

Patient Preference and Adherence
Chiara Whichello,1 Lars Viktrup,2 Oralee J Varnado,2 Matthew Quaife,1 Myrto Trapali,1 Antje Tockhorn-Heidenreich3 1Evidera, London, UK; 2Eli Lilly and Company, Indianapolis, IN, USA; 3Eli Lilly and Company, Bracknell, UKCorrespondence: Antje Tockhorn ...
Whichello C, Viktrup L, Varnado OJ, Quaife M, Trapali M, Tockhorn-Heidenreich A   +5 more
doaj  

Recognizing the role of CGRP and CGRP receptors in migraine and its treatment

, 2017
PREMISE: The brain and the sensory nervous system contain a rich supply of calcitonin gene-related peptide (CGRP) and CGRP receptor components. Clinical studies have demonstrated a correlation between CGRP release and acute migraine headache that led to ...
Edvinsson, Lars, Warfvinge, Karin, Lars Edvinsson, Karin Warfvinge   +3 more
core   +1 more source

Efficacy and safety of oral gepants for acute and preventive treatment of migraine: a systematic review of randomized placebo-controlled clinical trials

Headache Medicine
Introduction Migraine is a disabling neurological disorder affecting approximately 15% of the global population. Calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) represent a novel oral therapeutic class developed specifically for ...
Laryssa Raphaely Vieira da Silva, Celiane Mendes da Silva, Maria Fernanda Silva dos Santos, Letícia Padilha Pereira Cavalcante, Luna Matos Capocci, Larissa Karla Santos de Santana Alves, Richelly Beatryz Alves de Vasconcelos, Clara Nolasco Pinto Monteiro, Herculano Ramirez Floro Alonso, Mário César de Lima Silva, Alden Rodrigues de Albuquerque, Letícia Januzi de Almeida Rocha   +11 more
doaj   +2 more sources

Real-World Effectiveness of CGRP Antagonists in Patients with Migraine and Cluster Headache: A Study Protocol [PDF]

Background Scientific Gap Despite FDA approval of CGRP antagonists (gepant) in 2019, their realworld effectiveness and utilization patterns remain underexplored.
Ghosh, BS, Shreya, Wang, MD, Victor, Yuan, MD, PhD, Hsiangkuo, Malhan, DO/MS, Suraj, Spare, DO, Nicole, Marmura, MD, Michael, Nisar, MD, Areeba   +6 more
core  

Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents. [PDF]

Curr Pain Headache Rep
Shin L, Moon R, Gelfand A.
europepmc   +1 more source

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. [PDF]

Headache
Iannone LF, Silvestro M, Munafò A, Romozzi M, Geppetti P, Russo A.   +5 more
europepmc   +1 more source

Efficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant. [PDF]

J Oral Facial Pain Headache
Gautier A, Gicquel T, Mercerolle M, Le Daré B.   +3 more
europepmc   +1 more source

Patient Preferences Toward CGRP-Targeting Preventive Migraine Treatments in Japan: Discrete Choice Experiment. [PDF]

Neurol Ther
Igarashi H, Yamazaki T, Hanada K, Onomura H, Hozawa H, Murata T.   +5 more
europepmc   +1 more source

Triptans and Lasmiditan Are Safe and Effective in Patients with Migraine Attacks Associated with Neurodevelopmental Disorders: A Single-Center Prospective Clinical Case Series. [PDF]

Brain Sci
Shibata Y.
europepmc   +1 more source